FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
vasililiyluli,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kung Winston			PM	2. Issuer Name and Ticker or Trading Symbol PMV Pharmaceuticals, Inc. [PMVP]					(Ch	eck all applic Directo V Officer	able)	ng Person(s) to Issu 10% Own Other (sp		ner				
(Last)	`	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/12/2023							below)	COO, CF		below)		
C/O PMV PHARMACEUTICALS, INC. ONE RESEARCH WAY					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) PRINCE	TON N	J	08540										Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	state)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication												
Check this box to indicate that a transact satisfy the affirmative defense condition								n was made pursuant to a contract, instruction or written plan that is intended to f Rule 10b5-1(c). See Instruction 10.										
		Tal	ole I - Nor	n-Deriv	ative	Se	curities	s Ac	quired, [Disp	osed o	of, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)					eay/Year) Execut		Deemed ecution Date, any onth/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (ADisposed Of (D) (Instr. 3) 5)			Beneficia Owned F	ies For cially (D) Following (I) (Direct C Indirect E tr. 4)	7. Nature of Indirect Beneficial Ownership		
					Code	v	Amount	(A) (D)	or Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
			ransact ode (In	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	y G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code V		(A)	(D)	Date Exercisable		piration ite	Title	Amount or Number of Shares		(Instr. 4)			
Employee Stock Option (right to buy)	\$5.7	05/12/2023			A		150,000		(1)	05.	/12/2033	Common Stock	150,000	\$0.00	150,000)	D	

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.

Remarks:

/s/ Winston Kung

05/15/2023

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.